Peringatan Keamanan

An overdose of Melperone may result in cardiac arrhythmias T110, A31862.

Melperone

DB09224

small molecule investigational

Deskripsi

Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union L1316. It has been well established in the treatment of confusion, anxiety, restlessness (particularly in the elderly) and schizophrenia as It is known to be well-tolerated with an excellent safety profile. Recently, it has been studied as a treatment of psychosis related to Parkinson's disease L1316.

Struktur Molekul 2D

Berat 263.356
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Approximately 3-4 hours after oral administration [A31862]. After intramuscular injection, the half-life has been found to be approximately 6 hours [A31862].
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Oral doses are rapidly absorbed (Tmax 1.5–3.0 hours post oral ingestion)L1345.

Metabolisme

Mainly hepatic L1323.

Rute Eliminasi

Excreted mainly in the urine, with small amounts of unchanged drug L1323.

Interaksi Obat

1696 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Melperone.
Buprenorphine Melperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Melperone.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Melperone.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Melperone.
Hydrocodone Melperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium sulfate The therapeutic efficacy of Melperone can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Melperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Melperone may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Melperone.
Mirtazapine Melperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Melperone.
Orphenadrine Melperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Melperone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Melperone.
Rotigotine Melperone may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Melperone.
Sodium oxybate Melperone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Melperone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Melperone.
Thalidomide Melperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Melperone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Amisulpride Melperone may increase the antipsychotic activities of Amisulpride.
Methylphenidate The risk or severity of adverse effects can be increased when Melperone is combined with Methylphenidate.
Dexmethylphenidate The risk or severity of adverse effects can be increased when Melperone is combined with Dexmethylphenidate.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Melperone.
Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Melperone.
Sulpiride Melperone may increase the antipsychotic activities of Sulpiride.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Melperone.
Lithium hydroxide Lithium hydroxide may increase the neurotoxic activities of Melperone.
Lithium citrate Lithium citrate may increase the neurotoxic activities of Melperone.
Mequitazine Melperone may increase the arrhythmogenic activities of Mequitazine.
Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Melperone.
Ethanol Melperone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Melperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Melperone.
Zimelidine The risk or severity of adverse effects can be increased when Melperone is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Melperone is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Melperone is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Melperone is combined with Fluvoxamine.
Duloxetine The risk or severity of adverse effects can be increased when Melperone is combined with Duloxetine.
Paroxetine The risk or severity of adverse effects can be increased when Melperone is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Melperone is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Melperone is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Melperone is combined with Nefazodone.
Milnacipran The risk or severity of adverse effects can be increased when Melperone is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Melperone is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Melperone.
Indalpine The risk or severity of adverse effects can be increased when Melperone is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Melperone is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Melperone is combined with Alaproclate.
Carbidopa The therapeutic efficacy of Carbidopa can be decreased when used in combination with Melperone.
Cabergoline The therapeutic efficacy of Cabergoline can be decreased when used in combination with Melperone.
Tolcapone The therapeutic efficacy of Tolcapone can be decreased when used in combination with Melperone.
Metixene The therapeutic efficacy of Metixene can be decreased when used in combination with Melperone.
Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Melperone.
Procyclidine The therapeutic efficacy of Procyclidine can be decreased when used in combination with Melperone.
Profenamine The therapeutic efficacy of Profenamine can be decreased when used in combination with Melperone.
Entacapone The therapeutic efficacy of Entacapone can be decreased when used in combination with Melperone.
Lisuride The therapeutic efficacy of Lisuride can be decreased when used in combination with Melperone.
Apomorphine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Melperone.
Biperiden The therapeutic efficacy of Biperiden can be decreased when used in combination with Melperone.
Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Melperone.
Memantine The therapeutic efficacy of Memantine can be decreased when used in combination with Melperone.
Pergolide The therapeutic efficacy of Pergolide can be decreased when used in combination with Melperone.
Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Melperone.
Levodopa The therapeutic efficacy of Levodopa can be decreased when used in combination with Melperone.
Rasagiline The therapeutic efficacy of Rasagiline can be decreased when used in combination with Melperone.
3,5-Dinitrocatechol The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Melperone.
Etilevodopa The therapeutic efficacy of Etilevodopa can be decreased when used in combination with Melperone.
Safinamide The therapeutic efficacy of Safinamide can be decreased when used in combination with Melperone.
Ifenprodil The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Melperone.
Dexetimide The therapeutic efficacy of Dexetimide can be decreased when used in combination with Melperone.
Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Melperone.
Piribedil The therapeutic efficacy of Piribedil can be decreased when used in combination with Melperone.
Benserazide The therapeutic efficacy of Benserazide can be decreased when used in combination with Melperone.
Tropatepine The therapeutic efficacy of Tropatepine can be decreased when used in combination with Melperone.
Melevodopa The therapeutic efficacy of Melevodopa can be decreased when used in combination with Melperone.
Dihydroergocryptine The therapeutic efficacy of Dihydroergocryptine can be decreased when used in combination with Melperone.
Phenglutarimide The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Melperone.
Mazaticol The therapeutic efficacy of Mazaticol can be decreased when used in combination with Melperone.
Etybenzatropine The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Melperone.
Budipine The therapeutic efficacy of Budipine can be decreased when used in combination with Melperone.
Bornaprine The therapeutic efficacy of Bornaprine can be decreased when used in combination with Melperone.
Etanautine The therapeutic efficacy of Etanautine can be decreased when used in combination with Melperone.
Dexpramipexole The therapeutic efficacy of Dexpramipexole can be decreased when used in combination with Melperone.
Acetyldigitoxin Acetyldigitoxin may increase the arrhythmogenic activities of Melperone.
Lercanidipine Lercanidipine may increase the arrhythmogenic activities of Melperone.
Tocainide Tocainide may increase the arrhythmogenic activities of Melperone.
Deslanoside Deslanoside may increase the arrhythmogenic activities of Melperone.
Dexpropranolol Dexpropranolol may increase the arrhythmogenic activities of Melperone.
Cyclandelate Cyclandelate may increase the arrhythmogenic activities of Melperone.
Seletracetam Seletracetam may increase the arrhythmogenic activities of Melperone.
Nylidrin Nylidrin may increase the arrhythmogenic activities of Melperone.
Xylometazoline Xylometazoline may increase the arrhythmogenic activities of Melperone.
Tranilast Tranilast may increase the arrhythmogenic activities of Melperone.
Fasudil Fasudil may increase the arrhythmogenic activities of Melperone.
Agmatine Agmatine may increase the arrhythmogenic activities of Melperone.
Carteolol Melperone may increase the arrhythmogenic activities of Carteolol.
Metipranolol Melperone may increase the arrhythmogenic activities of Metipranolol.

Target Protein

D(2) dopamine receptor DRD2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 7140807
    Borgstrom L, Larsson H, Molander L: Pharmacokinetics of parenteral and oral melperone in man. Eur J Clin Pharmacol. 1982;23(2):173-6.
  • PMID: 12765745
    Sumiyoshi T, Jayathilake K, Meltzer HY: A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia. Schizophr Res. 2003 Jul 1;62(1-2):65-72.
  • PMID: 1688972
    Hui WK, Mitchell LB, Kavanagh KM, Gillis AM, Wyse DG, Manyari DE, Duff HJ: Melperone: electrophysiologic and antiarrhythmic activity in humans. J Cardiovasc Pharmacol. 1990 Jan;15(1):144-9.
Textbook
  • Koppel, J et al. (1988). Gas chromatographic- mass spectrometric study of urinary metabolism of melperone. Journal of Biomedical Chromatography.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Bunil

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul